Background The optimal timing for SARS-CoV-2 vaccines within the first year after
allogeneic hematopoietic cell transplant (HCT) is poorly understood. Methods We conducted …

Vaccines against SARS-CoV-2 have been rapidly approved. Although pivotal studies were
conducted in healthy volunteers, little information is available on the safety and efficacy of …

In allogeneic stem cell transplant (Allo-SCT) recipients, the cell-mediated and humoral
immunogenicity of the 3-dose SARS-CoV-2 vaccination schedule has not been investigated …

Recipients after hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor
T-cell (CAR-T) therapy are at increased risk for unfavorable outcomes after SARS-CoV-2 …

A full exploration of immune responses is deserved after anti-SARS-CoV-2 vaccination and
boosters, especially in the context of allogeneic hematopoietic stem cell transplantation (allo …

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment
for a wide range of hematological diseases but is still associated with significant infection …

(1) Background: mRNA COVID-19 vaccines are effective but show varied efficacy in
immunocompromised patients, including allogeneic hematopoietic stem cell transplant …

The kinetics of SARS-CoV-2 reactive IgG antibodies after full vaccination and booster in
allogeneic and autologous stem cell transplantation (allo-HSCT, ASCT) and chimeric …

Introduction Patients after allogeneic stem cell transplantation are at high risk for infection‐
related complications, and vaccination efficacy might be impaired depending on the immune …

Patients with hematological malignancies (HM) undergoing hematopoietic stem cell
transplantation (HSCT) have an increased vulnerability to SARS-Cov-2 (Sharma et al …